The campaign is the first-of-its-kind partnership and follows the US FDA approval of Motiva Implants® NEW YORK , March 6, 2025 /PRNewswire/ -- Establishment Labs® Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced a partnership with GRAMMY Award-winning hitmaker Meghan Trainor. Meghan recently received Motiva Implants® after careful consideration and research.
Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $0.79 per share a year ago.
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced its participation in a fireside chat at Citi's 2025 Unplugged Medtech and Life Sciences Access Day. Juan José Chacón-Quirós, Chief Executive Officer and Founder; Peter Caldini, President; and Raj Denhoy, Chief Financial Officer, are scheduled to present on Thursday,.
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended December 31, 2024, after the market closes on Wednesday, February 26, 2025, and will host a conference call at 4:30 pm ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S.
Establishment Labs Holdings Inc. (NASDAQ:ESTA ) Q3 2024 Earnings Call Transcript November 7, 2024 4:30 PM ET Company Participants Rajbir Denhoy - Chief Financial Officer Juan Jose - CEO and Founder Conference Call Participants Allen Gong - JPMorgan Matt Taylor - Jefferies Sam Eiber - BTIG Anthony Pettinari - Citi Josh Jennings - TD Cowen Anthony Petrone - Mizuho Group Operator Good afternoon. Welcome to Establishment Labs Third Quarter 2024 Earnings Conference Call.
Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $1.12 per share a year ago.
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (Nasdaq: ESTA) (the “Company”), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced that it has entered into a securities purchase agreement (the “Purchase Agreement”) with select purchasers for the purchase of 765,696 common shares and pre-funded warrants to purchase up to 328,161 common shares in a registered direct offering for a.
NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced it has received approval from the U.S. Food and Drug Administration (FDA) for the use of Motiva® SmoothSilk® Ergonomix® and Motiva® SmoothSilk® Round breast implants in primary and revision breast augmentation. “Today's approval is transformative for breast aesthetics in.
Establishment Labs Holdings Inc. (ESTA) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to loss of $0.65 per share a year ago.
Establishment Labs (ESTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.